Purtscher-like retinopathy secondary to acute pancreatitis: a case report – one year treatment observation and patient recovery

Session Details

Session Title: Presented Poster Session: Ocular Pathologies

Venue: Poster Village: Pod 3

First Author: : W.Luboń POLAND

Co Author(s): :    A. Kabiesz   K. Jadczyk-Sorek   E. Mrukwa-Kominek                 

Abstract Details

Purpose:

Purpose of this study is to present the results of treatment the patient with purtscher-like retinopathy secondary to acute pancreatitis and demonstration of therapeutic efficiency and possible complications after one year time.

Setting:

Department Of Ophthalmology, School Of Medicine In Katowice, Medical University Of Silesia, Katowice, Poland The University Clinical Centre Prof Kornel Gibiński, Department Of Ophthalmology, Medical University Of Silesia, Katowice, Poland

Methods:

the patient with purtscher-like retinopathy secondary to acute pancreatitis. The diagnosis was based on examination of the front and back part of the eyes in slit lamp and ophthalmocsope, extended by fluorescein angiography and optical coherence tomography of the retina and optic disc.

Results:

From the onset of symptoms to the administration passed the time of 12 days. Patient controls were held on schedule : 2 weeks, 1 month, 3 months, 6 months, 12 months since the onset of symptoms and included measurements of visual acuity, intraocular pressure, optical coherence tomography of the retina and the optic disc, visual field testing - kinetic and static perimetry, fluorescein angiography, and electrophysiology examination of the eyes.In the presented patient with purtscher-like retinopathy secondary to acute pancreatitis the use of steroids and antibiotics resulted in improved visual acuity and reduced retinal hemorrhage and optic disc edema.

Conclusions:

The used drugs resulted in partial improvement of functional and morphological conditions of central retina. A one year follow up after treatment showed functional and morphological stabilisation of central retina and no recurrence of the disease.

Financial Disclosure:

None